Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
根據最新的財務報表(Form-10K),WuXi Biologics (Cayman) Inc. 的總資產為 $56,977,淨利潤為 $3,356
WXXWY 的關鍵財務比率是什麼?
WuXi Biologics (Cayman) Inc. 的流動比率為 3.75,淨利潤率為 17.97,每股銷售為 $4.41。
WuXi Biologics (Cayman) Inc. 的收入按細分市場或地理位置如何劃分?
WuXi Biologics (Cayman) Inc. 最大收入來源為 Biologics,在最近的收益報告中收入為 15,972,158,570。就地區而言,North America 是 WuXi Biologics (Cayman) Inc. 的主要市場,收入為 11,596,649,464。
WuXi Biologics (Cayman) Inc. 是否盈利?
是的,根據最新的財務報表,WuXi Biologics (Cayman) Inc. 的淨利潤為 $3,356